INS and prostate carcinoma: High insulin levels are known to be an adverse prognostic factor for a number of cancers, including breast, colon, and prostate cancer [8, 24, 25], and metformin has been shown to be able to lower systemic insulin levels, even in non-diabetic patients [9].